Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non Operating Income: 2010-2024

Historic Other Non Operating Income for Northwest Biotherapeutics (NWBO) over the last 14 years, with Dec 2024 value amounting to -$17.3 million.

  • Northwest Biotherapeutics' Other Non Operating Income fell 83.42% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.7 million, marking a year-over-year decrease of 444.75%. This contributed to the annual value of -$17.3 million for FY2024, which is 143.55% down from last year.
  • According to the latest figures from FY2024, Northwest Biotherapeutics' Other Non Operating Income is -$17.3 million, which was down 143.55% from -$7.1 million recorded in FY2023.
  • Northwest Biotherapeutics' Other Non Operating Income's 5-year high stood at $239.3 million during FY2021, with a 5-year trough of -$443.2 million in FY2020.
  • For the 3-year period, Northwest Biotherapeutics' Other Non Operating Income averaged around -$20.7 million, with its median value being -$17.3 million (2024).
  • As far as peak fluctuations go, Northwest Biotherapeutics' Other Non Operating Income crashed by 3,847.18% in 2020, and later spiked by 154.00% in 2021.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Other Non Operating Income stood at -$443.2 million in 2020, then soared by 154.00% to $239.3 million in 2021, then plummeted by 115.81% to -$37.9 million in 2022, then spiked by 81.27% to -$7.1 million in 2023, then crashed by 143.55% to -$17.3 million in 2024.